The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
about
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Heat shock protein 90 inhibition: rationale and clinical potential.Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 SpeciesAutophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.Successful establishment of patient-derived tumor xenografts from gastrointestinal stromal tumor-a single center experienceDiscovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.GIST treatment options after tyrosine kinase inhibitors.The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.New targets and therapies for gastrointestinal stromal tumors.
P2860
Q27851995-A9946907-8B28-49DA-848F-5912DA126616Q30418761-0885B073-DD3E-4670-8974-603D7314C0C4Q34052411-AC444DEF-FD66-4979-8873-E4EB6A9990D4Q34289180-BC716872-AA3B-49AE-9B24-C9D5E94DF047Q34957090-ABB2ACC8-747F-44A1-9E39-E1743C68D4C1Q35555471-FBFC67F2-99A1-404B-A18F-6B6AFBDFAC5EQ36426254-41CFF2F9-3619-4FAA-B806-F05B22A56E60Q36556257-4AE3E6F1-737A-48C3-ABD2-0558B0C4CFBFQ36874692-2737CF75-C077-4098-87CF-E3F98D2E377CQ38103907-1F6198DA-20D1-4DDE-95B8-7D9A045A0376Q38222205-3FB5CC76-DD11-4CF5-8165-E74B138A51F3Q38833685-C08D42B0-2A27-4857-BE52-ED9CD0C70F12Q38976702-D0A31964-6E0C-4E43-B141-0588934A6136Q39288497-DBB994DE-FFEE-481C-ABB7-EF45F5ABB8F7Q47432725-37ED7A3E-4878-4340-8A0E-055259D59FB7
P2860
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@en
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@nl
type
label
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@en
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@nl
prefLabel
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@en
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@nl
P50
P1476
The Novel HSP90 inhibitor, IPI ...... g heterogeneous KIT mutations.
@en
P2093
Emmanuel Normant
Thomas Van Looy
P304
P356
10.1158/1078-0432.CCR-11-0562
P407
P50
P577
2011-07-07T00:00:00Z